FusionNeoAntigen Logo

Home

Download

Statistics

Examples

Help

Contact

Terms of Use

Center for Computational Systems Medicine
leaf

Fusion Gene and Fusion Protein Summary

leaf

Fusion Amino Acid Sequences (multiple BPs and multiple gene isoforms)

leaf

Fusion Protein Breakpoint Sequences - (for the Screening of the FusionNeoAntigens)

leaf

Potential FusionNeoAntigens in HLA I - (netMHCpan v4.1 + deepHLApan v1.1)

leaf

Potential FusionNeoAntigens in HLA II - (netMHCIIpan v4.1)

leaf

Fusion Breakpoint 14 AA Peptide Structure - (RoseTTAFold)

leaf

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D - (Glide)

leaf

Vaccine Design for the FusionNeoAntigens (RNA/protein sequences)

leaf

Potential target of CAR-T therapy development

leaf

Information on the samples that have these potential fusion neoantigens

leaf

Fusion Protein Targeting Drugs - (Manual Curation)

leaf

Fusion Protein Related diseases - (Manual Curation)

Fusion Protein:PCMTD1-UBE2E1

Fusion Gene and Fusion Protein Summary

check button Fusion gene summary
Fusion partner gene informationFusion gene name: PCMTD1-UBE2E1
FusionPDB ID: 63383
FusionGDB2.0 ID: 63383
HgeneTgene
Gene symbol

PCMTD1

UBE2E1

Gene ID

115294

7324

Gene nameprotein-L-isoaspartate (D-aspartate) O-methyltransferase domain containing 1ubiquitin conjugating enzyme E2 E1
Synonyms-UBCH6
Cytomap

8q11.23

3p24.2

Type of geneprotein-codingprotein-coding
Descriptionprotein-L-isoaspartate O-methyltransferase domain-containing protein 1ubiquitin-conjugating enzyme E2 E1(E3-independent) E2 ubiquitin-conjugating enzyme E1E2 ubiquitin-conjugating enzyme E1ubiquitin carrier protein E1ubiquitin conjugating enzyme E2E 1ubiquitin-conjugating enzyme E2E 1 (UBC4/5 homolog, yeast)ubiquitin-
Modification date2020031320200313
UniProtAcc..
Ensembl transtripts involved in fusion geneENST idsENST00000360540, ENST00000522514, 
ENST00000519559, ENST00000521344, 
ENST00000544451, 
ENST00000475680, 
ENST00000346855, ENST00000424381, 
ENST00000467766, ENST00000306627, 
Fusion gene scores for assessment (based on all fusion genes of FusionGDB 2.0)* DoF score27 X 12 X 15=48604 X 4 X 2=32
# samples 404
** MAII scorelog2(40/4860*10)=-3.60288440871842
possibly effective Gene in Pan-Cancer Fusion Genes (peGinPCFGs).
DoF>8 and MAII<0
log2(4/32*10)=0.321928094887362
effective Gene in Pan-Cancer Fusion Genes (eGinPCFGs).
DoF>8 and MAII>0
Fusion gene context

PubMed: PCMTD1 [Title/Abstract] AND UBE2E1 [Title/Abstract] AND fusion [Title/Abstract]

Fusion neoantigen context

PubMed: PCMTD1 [Title/Abstract] AND UBE2E1 [Title/Abstract] AND neoantigen [Title/Abstract]

Most frequent breakpoint (based on all fusion genes of FusionGDB 2.0)PCMTD1(52758220)-UBE2E1(23852950), # samples:1
Anticipated loss of major functional domain due to fusion event.PCMTD1-UBE2E1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
PCMTD1-UBE2E1 seems lost the major protein functional domain in Hgene partner, which is a CGC by not retaining the major functional domain in the partially deleted in-frame ORF.
PCMTD1-UBE2E1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
PCMTD1-UBE2E1 seems lost the major protein functional domain in Hgene partner, which is a essential gene by not retaining the major functional domain in the partially deleted in-frame ORF.
PCMTD1-UBE2E1 seems lost the major protein functional domain in Tgene partner, which is a epigenetic factor due to the frame-shifted ORF.
PCMTD1-UBE2E1 seems lost the major protein functional domain in Tgene partner, which is a essential gene due to the frame-shifted ORF.
* DoF score (Degree of Frequency) = # partners X # break points X # cancer types
** MAII score (Major Active Isofusion Index) = log2(# samples/DoF score*10)

check button Gene ontology of each fusion partner gene with evidence of Inferred from Direct Assay (IDA) from Entrez
PartnerGeneGO IDGO termPubMed ID
TgeneUBE2E1

GO:0000209

protein polyubiquitination

15247280|16522193

TgeneUBE2E1

GO:0010390

histone monoubiquitination

16307923

TgeneUBE2E1

GO:0016567

protein ubiquitination

9990509

TgeneUBE2E1

GO:0032020

ISG15-protein conjugation

16428300

TgeneUBE2E1

GO:0033523

histone H2B ubiquitination

16307923

TgeneUBE2E1

GO:0070936

protein K48-linked ubiquitination

20061386



check button Four levels of functional features of fusion genes
Go to FGviewer search page for the most frequent breakpoint (https://ccsmweb.uth.edu/FGviewer/chr8:52758220/chr3:23852950)
- FGviewer provides the online visualization of the retention search of the protein functional features across DNA, RNA, protein, and pathological levels.
- How to search
1. Put your fusion gene symbol.
2. Press the tab key until there will be shown the breakpoint information filled.
4. Go down and press 'Search' tab twice.
4. Go down to have the hyperlink of the search result.
5. Click the hyperlink.
6. See the FGviewer result for your fusion gene.
FGviewer

check buttonRetention analysis results of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features, are available here.

check buttonFusion gene breakpoints across PCMTD1 (5'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure

check buttonFusion gene breakpoints across UBE2E1 (3'-gene)
* Click on the image to open the UCSC genome browser with custom track showing this image in a new window.
all structure


Top

Fusion Amino Acid Sequences


check buttonFusion information from ORFfinder translation from full-length transcript sequence from FusionPDB.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandSeq length
(transcript)
BP loci
(transcript)
Predicted start
(transcript)
Predicted stop
(transcript)
Seq length
(amino acids)
ENST00000522514PCMTD1chr852758220-ENST00000306627UBE2E1chr323852950+17526121901041283

check buttonDeepORF prediction of the coding potential based on the fusion transcript sequence of in-frame fusion genes. DeepORF is a coding potential classifier based on convolutional neural network by comparing the real Ribo-seq data. If the no-coding score < 0.5 and coding score > 0.5, then the in-frame fusion transcript is predicted as being likely translated.
HenstTenstHgeneHchrHbpHstrandTgeneTchrTbpTstrandNo-coding scoreCoding score
ENST00000522514ENST00000306627PCMTD1chr852758220-UBE2E1chr323852950+0.0002035370.99979645

check button Predicted full-length fusion amino acid sequences. For individual full-length fusion transcript sequence from FusionPDB, we ran ORFfinder and chose the longest ORF among all the predicted ones.

Get the fusion protein sequences from here.

Fusion protein sequence information is available in the fasta format.
>FusionGDB ID_FusionGDB isoform ID_FGname_Hgene_Hchr_Hbp_Henst_Tgene_Tchr_Tbp_Tenst_length(fusion AA) seq_BP

Top

Fusion Protein Breakpoint Sequences for PCMTD1-UBE2E1

check button +/-13 AA sequence from the breakpoints of the fusion protein sequences.
HgeneHchrHbpTgeneTchrTbpLength(fusion protein)BP in fusion proteinPeptide
PCMTD1chr852758220UBE2E1chr323852950612141LESFIKNSDSFDKIQKELADITLDPP

Top

Potential FusionNeoAntigen Information of PCMTD1-UBE2E1 in HLA I

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
PCMTD1-UBE2E1_52758220_23852950.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCpan v4.1 (%rank<0.5) and deepHLApan v1.1 (immunogenic score>0.5)
Fusion geneHchrHbpTgeneTchrTbpHLA IFusionNeoAntigen peptideBinding scoreImmunogenic scoreNeoantigen start (at BP 13)Neoantigen end (at BP 13)
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C08:15FDKIQKEL10.96481018
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C04:10FDKIQKEL10.75791018
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C04:07FDKIQKEL10.75821018
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C04:14FDKIQKEL0.99780.79421018
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C05:09SFDKIQKEL0.99990.9253918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C04:07SFDKIQKEL0.99980.8266918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C04:10SFDKIQKEL0.99980.8236918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C08:15SFDKIQKEL0.99970.9619918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C01:17SFDKIQKEL0.99940.9226918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C01:30SFDKIQKEL0.99410.9646918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C07:05SFDKIQKEL0.99260.9718918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C07:10SFDKIQKEL0.99040.9662918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C08:04SFDKIQKEL0.99010.9584918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C08:13SFDKIQKEL0.99010.9584918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C07:29SFDKIQKEL0.98930.9365918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C04:06SFDKIQKEL0.98930.8723918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C07:67SFDKIQKEL0.98720.9595918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C07:80SFDKIQKEL0.98720.9595918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C07:13SFDKIQKEL0.9860.9268918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C07:27SFDKIQKEL0.98550.9683918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C07:19SFDKIQKEL0.98490.7865918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C07:95SFDKIQKEL0.98380.7593918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C07:46SFDKIQKEL0.98070.8934918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C08:03SFDKIQKEL0.95820.9759918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C04:14SFDKIQKEL0.93120.8655918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-B14:03SFDKIQKEL0.81550.8201918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-B39:09SFDKIQKEL0.8140.5063918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-B39:08SFDKIQKEL0.79750.6898918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-B39:12SFDKIQKEL0.70620.8211918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C12:16SFDKIQKEL0.63360.9571918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-A02:07SFDKIQKEL0.60320.5396918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C18:01FDKIQKEL10.79251018
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C04:01FDKIQKEL10.75821018
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C08:02FDKIQKEL10.96481018
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C04:03SFDKIQKEL0.99990.8638918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C05:01SFDKIQKEL0.99990.9253918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C18:01SFDKIQKEL0.99980.8387918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C04:01SFDKIQKEL0.99980.8266918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C01:03SFDKIQKEL0.99970.8837918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C08:02SFDKIQKEL0.99970.9619918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C01:02SFDKIQKEL0.99960.9226918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C06:06SFDKIQKEL0.99780.9866918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C03:67SFDKIQKEL0.99770.9795918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C14:02SFDKIQKEL0.9940.941918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C14:03SFDKIQKEL0.9940.941918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C07:17SFDKIQKEL0.98820.9624918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C07:02SFDKIQKEL0.98720.9595918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C07:01SFDKIQKEL0.98290.7534918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C04:04SFDKIQKEL0.98240.867918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C07:04SFDKIQKEL0.9790.9276918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-C08:01SFDKIQKEL0.95820.9759918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-B39:11SFDKIQKEL0.7960.6143918
PCMTD1-UBE2E1chr852758220chr323852950612HLA-B07:13SFDKIQKEL0.14540.7051918

Top

Potential FusionNeoAntigen Information of PCMTD1-UBE2E1 in HLA II

check button Multiple sequence alignments of the potential FusionNeoAntigens per fusion breakpoints. If the MSA is empty, then it means that there were predicted fusion neoantigens in this fusion breakpoint, but those predicted fusion neoantigens were not across the breakpoint, which is not fusion-specific.
PCMTD1-UBE2E1_52758220_23852950.msa

check button Potential FusionNeoAntigen Information
* We used NetMHCIIpan v4.1 (%rank<0.5).
Fusion geneHchrHbpTgeneTchrTbpHLA IIFusionNeoAntigen peptideNeoantigen start (at BP 13)Neoantigen end (at BP 13)
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-0409LESFIKNSDSFDKIQ015
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-0417LESFIKNSDSFDKIQ015
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-0466SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-0480LESFIKNSDSFDKIQ015
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-0802SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-0802NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-0808SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-0809SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-0809NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-0811SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-0821SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-0821NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-0824SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-0824NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-0824KNSDSFDKIQKELAD520
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1101SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1101NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1105SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1105NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1108SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1108NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1109SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1109NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1110SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1110NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1112SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1112NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1115SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1115NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1119SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1119NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1124SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1124NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1127SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1127NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1128SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1128NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1129SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1129NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1131SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1131NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1132SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1132NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1133SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1133NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1137SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1137NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1137KNSDSFDKIQKELAD520
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1139SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1139NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1149SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1149NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1151SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1151NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1153SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1153NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1161SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1161NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1162SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1162NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1166SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1166NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1169SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1172SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1172NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1173SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1173NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1174SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1174NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1175SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1175NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1180SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1180NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1180KNSDSFDKIQKELAD520
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1181SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1181NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1181KNSDSFDKIQKELAD520
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1187SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1187NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1187KNSDSFDKIQKELAD520
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1190SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1190NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1191SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1191NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1191KNSDSFDKIQKELAD520
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1193SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1193NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1193KNSDSFDKIQKELAD520
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1194SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1194NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1195SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1195NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1196SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1196NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1305SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1305NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1307SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1307NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1307KNSDSFDKIQKELAD520
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-13100SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-13100NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1314SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1314NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1326SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1326NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1337SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1337NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1346SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1346NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1347SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1347NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1349SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1350SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1350NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1356SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1356NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1360SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1360NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1362SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1362NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1382SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1382NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1385SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1385NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1386SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1402SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1402NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1409SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1409NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1414SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1414NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1422SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1422NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1422KNSDSFDKIQKELAD520
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1425SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1425NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1425KNSDSFDKIQKELAD520
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1427SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1430SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1430NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1436SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1436NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1441SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1441NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1442SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1444SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1444NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1451SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1451NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1453SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1453NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1469SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1469NSDSFDKIQKELADI621
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1494SDSFDKIQKELADIT722
PCMTD1-UBE2E1chr852758220chr323852950612DRB1-1494NSDSFDKIQKELADI621

Top

Fusion breakpoint peptide structures of PCMTD1-UBE2E1

check button3D structures of the fusion breakpoint peptide of 14AA sequence that have potential fusion neoantigens
* The minimum length of the amino acid sequence in RoseTTAFold is 14AA. Here, we predicted the 14AA fusion protein breakpoint sequence not the fusion neoantigen peptide, which is shorter than 14 AA.
File nameBPseqHgeneTgeneHchrHbpTchrTbpAAlen
6371NSDSFDKIQKELADPCMTD1UBE2E1chr852758220chr323852950612

Top

Filtering FusionNeoAntigens Through Checking the Interaction with HLAs in 3D of PCMTD1-UBE2E1

check buttonVirtual screening between 25 HLAs (from PDB) and FusionNeoAntigens
* We used Glide to predict the interaction between HLAs and neoantigens.
HLA allelePDB IDFile nameBPseqDocking scoreGlide score
HLA-B14:023BVN6371NSDSFDKIQKELAD-7.52345-7.63685
HLA-B14:023BVN6371NSDSFDKIQKELAD-4.30785-5.34315
HLA-B52:013W396371NSDSFDKIQKELAD-6.79163-7.82693
HLA-B52:013W396371NSDSFDKIQKELAD-6.57313-6.68653
HLA-B18:014JQV6371NSDSFDKIQKELAD-4.90024-5.93554
HLA-A24:025HGA6371NSDSFDKIQKELAD-8.47128-8.58468
HLA-A24:025HGA6371NSDSFDKIQKELAD-5.90441-6.93971
HLA-B44:053DX86371NSDSFDKIQKELAD-5.48457-6.51987
HLA-B44:053DX86371NSDSFDKIQKELAD-4.4693-4.5827
HLA-A02:016TDR6371NSDSFDKIQKELAD-0.786276-1.82158

Top

Vaccine Design for the FusionNeoAntigens of PCMTD1-UBE2E1

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-Is.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptide sequenceFusionNeoAntigen RNA sequence
PCMTD1-UBE2E1chr852758220chr3238529501018FDKIQKELCTTTGATAAAATTCAGAAGGAGCT
PCMTD1-UBE2E1chr852758220chr323852950918SFDKIQKELTAGCTTTGATAAAATTCAGAAGGAGCT

check button mRNA and peptide sequences of FusionNeoAntigens that have potential interaction with HLA-IIs.
Fusion geneHchrHbpTchrTbpStart in +/-13AAEnd in +/-13AAFusionNeoAntigen peptideFusionNEoAntigen RNA sequence
PCMTD1-UBE2E1chr852758220chr323852950015LESFIKNSDSFDKIQACTGGAGAGCTTCATCAAAAATAGTGATAGCTTTGATAAAATTCA
PCMTD1-UBE2E1chr852758220chr323852950520KNSDSFDKIQKELADCAAAAATAGTGATAGCTTTGATAAAATTCAGAAGGAGCTGGCGGA
PCMTD1-UBE2E1chr852758220chr323852950621NSDSFDKIQKELADIAAATAGTGATAGCTTTGATAAAATTCAGAAGGAGCTGGCGGACAT
PCMTD1-UBE2E1chr852758220chr323852950722SDSFDKIQKELADITTAGTGATAGCTTTGATAAAATTCAGAAGGAGCTGGCGGACATCAC

Top

Information of the samples that have these potential fusion neoantigens of PCMTD1-UBE2E1

check button These samples were reported as having these fusion breakpoints. For individual breakpoints, we checked the open reading frames considering multiple gene isoforms and chose the in-frame fusion genes only. Then, we made fusion protein sequences and predicted the fusion neoantigens. These fusion-positive samples may have these potential fusion neoantigens.
Cancer typeFusion geneHchrHbpHenstTchrTbpTenstSample
BRCAPCMTD1-UBE2E1chr852758220ENST00000522514chr323852950ENST00000306627TCGA-BH-A18P

Top

Potential target of CAR-T therapy development for PCMTD1-UBE2E1

check button Predicted 3D structure. We used RoseTTAFold.

check buttonRetention analysis result of each fusion partner protein across 39 protein features of UniProt such as six molecule processing features, 13 region features, four site features, six amino acid modification features, two natural variation features, five experimental info features, and 3 secondary structure features. Here, to provide the retention of the transmembrane domain, we only show the protein feature retention information of those transmembrane features


* Minus value of BPloci means that the break point is located before the CDS.
- In-frame and retained 'Transmembrane'.
PartnerGeneHbpTbpENSTStrandBPexonTotalExonProtein feature loci*BPlociTotalLenProtein featureProtein feature note

check button Subcellular localization prediction of the transmembrane domain retained fusion proteins
* We used DeepLoc 1.0. The order of the X-axis of the barplot is as follows: Entry_ID, Localization, Type, Nucleus, Cytoplasm, Extracellular, Mitochondrion, Cell_membrane, Endoplasmic_reticulum, Plastid, Golgi.apparatus, Lysosome.Vacuole, Peroxisome. Y-axis is the output score of DeepLoc. Clicking the image will open a new tab with a large image.
HgeneHchrHbpHenstTgeneTchrTbpTenstDeepLoc result

Top

Related Drugs to PCMTD1-UBE2E1

check button Drugs used for this fusion-positive patient.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDrugSourcePMID

Top

Related Diseases to PCMTD1-UBE2E1

check button Diseases that have this fusion gene.
(Manual curation of PubMed, 04-30-2022 + MyCancerGenome)
HgeneTgeneDiseaseSourcePMID

check button Diseases associated with fusion partners.
(DisGeNet 4.0)
PartnerGeneDisease IDDisease name# pubmedsSource